Vol.

No.

June 25, 2021Jun 25, 2021

Free

DOWNLOAD THE PDF

Racial, ethnic minorities are systemically underrepresented in leadership teams across NCI cancer centers

Cover Story

Conversation with The Cancer Letter Free Health Equity

Racial, ethnic minorities are systemically underrepresented in leadership teams across NCI cancer centers

By Matthew Bin Han Ong

Racial and ethnic minorities that are underrepresented in medicine have even lower representation in leadership of NCI-designated cancer centers, a study by Memorial Sloan Kettering Cancer Center researchers found.

Free Health Equity

Will cancer centers remain committed to improving equity in the long term?
Cancer center leaders discuss their hiring and diversity pipeline efforts

By Matthew Bin Han Ong

Free Guest Editorial

Fly the pride flag—and free the LGBTQ+ community from the oppression of smoking

By Phoenix A. Matthews

Free Guest Editorial

Let’s stop passing the buck on sexual harassment in academic medicine

By Shikha Jain, Arghavan Salles and Vineet Arora

Free

Pazdur expresses “profound concerns” about single-arm studies of PD-1/PD-L1 drugs; ODAC nixes retifanlimab for anal cancer

By Paul Goldberg

Free

NCI BSA approves four new concepts, concurs with 31 reissue PARs

By Alexandria Carolan

Free In the Archives

Betty Ford and the press conference that changed oncology

By Katie Goldberg

In Brief

John H. Stewart named center director of LSU Health New Orleans/LCMC Health Cancer Center

Julio Aguirre-Ghiso named founding director of the Cancer Dormancy and Tumor Microenvironment Institute at Albert Einstein Cancer Center

Lauren Hackett named deputy director of administration at Albert Einstein Cancer Center

Erika Newman named Rogel Cancer Center’s first associate director for diversity, equity, inclusion and justice

Luisa Iruela-Arispe named co-leader of the TEAM Program at Lurie Comprehensive Cancer Center

Navneet Majhail named deputy physician-in-chief of blood cancers at Sarah Cannon

RWJBarnabas Health and Rutgers Cancer Institute of New Jersey break ground on Jack & Sheryl Morris Cancer Center

UCSF establishes $250M initiative to develop living therapeutics

COTA and UChicago collaborate to study racial disparities in cancer treatment

Cancer centers, Genentech launch oncology clinical trial diversity alliance

ASCO, Friends of Cancer Research: Individuals with cancer must be included in COVID-19 vaccine trials

Clinical Roundup

DFCI study: How cancers with common gene mutation develop resistance to targeted drugs

International study of rare childhood cancer finds genetic clues, potential for tailored therapy

USC Study shows inherited risk of early-onset cancer is higher among Latino, African American, and Asian/Pacific Islander families

UCI-led study finds that cancer immunotherapy may self-limit its efficacy

Study: combination treatment effective in IDH mutant cancers

Immunotherapy drug combination improves response in HER2-negative breast cancer, including a subset of estrogen receptor positive cancers

Yale Cancer Center study reveals new pathway for brain tumor therapy

Drugs & Targets

Libtayo approved by European Commission for first-line treatment of patients with advanced NSCLC with ≥50% PD-L1 expression

Abecma receives positive CHMP opinion for relapsed and refractory multiple myeloma

Opdivo receives positive CHMP opinion as adjuvant treatment for GEJ cancer patients with residual pathologic disease following chemoradiotherapy

European Commission approves Onureg for certain AML subtypes

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Racial, ethnic minorities are systemically underrepresented in leadership teams across NCI cancer centers

Will cancer centers remain committed to improving equity in the long term?
Cancer center leaders discuss their hiring and diversity pipeline efforts

Fly the pride flag—and free the LGBTQ+ community from the oppression of smoking

Let’s stop passing the buck on sexual harassment in academic medicine

Pazdur expresses “profound concerns” about single-arm studies of PD-1/PD-L1 drugs; ODAC nixes retifanlimab for anal cancer

NCI BSA approves four new concepts, concurs with 31 reissue PARs

Betty Ford and the press conference that changed oncology

In Brief

John H. Stewart named center director of LSU Health New Orleans/LCMC Health Cancer Center

Julio Aguirre-Ghiso named founding director of the Cancer Dormancy and Tumor Microenvironment Institute at Albert Einstein Cancer Center

Lauren Hackett named deputy director of administration at Albert Einstein Cancer Center

Erika Newman named Rogel Cancer Center’s first associate director for diversity, equity, inclusion and justice

Luisa Iruela-Arispe named co-leader of the TEAM Program at Lurie Comprehensive Cancer Center

Navneet Majhail named deputy physician-in-chief of blood cancers at Sarah Cannon

RWJBarnabas Health and Rutgers Cancer Institute of New Jersey break ground on Jack & Sheryl Morris Cancer Center

UCSF establishes $250M initiative to develop living therapeutics

COTA and UChicago collaborate to study racial disparities in cancer treatment

Cancer centers, Genentech launch oncology clinical trial diversity alliance

ASCO, Friends of Cancer Research: Individuals with cancer must be included in COVID-19 vaccine trials

Clinical Roundup

DFCI study: How cancers with common gene mutation develop resistance to targeted drugs

International study of rare childhood cancer finds genetic clues, potential for tailored therapy

USC Study shows inherited risk of early-onset cancer is higher among Latino, African American, and Asian/Pacific Islander families

UCI-led study finds that cancer immunotherapy may self-limit its efficacy

Study: combination treatment effective in IDH mutant cancers

Immunotherapy drug combination improves response in HER2-negative breast cancer, including a subset of estrogen receptor positive cancers

Yale Cancer Center study reveals new pathway for brain tumor therapy

Drugs & Targets

Libtayo approved by European Commission for first-line treatment of patients with advanced NSCLC with ≥50% PD-L1 expression

Abecma receives positive CHMP opinion for relapsed and refractory multiple myeloma

Opdivo receives positive CHMP opinion as adjuvant treatment for GEJ cancer patients with residual pathologic disease following chemoradiotherapy

European Commission approves Onureg for certain AML subtypes

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login